Altimmune falls as CEO Vipin Garg to step down

Shares of drug developer Altimmune ALT.O fall 6.7% to $4.91 premarket

Co says Chairman Jerry Durso will take over as chief executive officer on January 1, 2026, succeeding Vipin Garg, who has led the company for seven years

Co says Durso previously led Intercept Pharmaceuticals and spent over 20 years at Sanofi SASY.PA

Co's lead drug pemvidutide is being developed for liver disease and weight loss - ALT

ALT expects 48-week mid-stage trial data and FDA meeting on proposed late-stage study before year-end, co says

Up to last close, stock down ~27% YTD